Pfizer's manufacturing facility in Tamil Nadu’s Sriperumbudur
is not following quality control norms and lacks data related to laboratory records. These are among the 11 observations the US Food and Drug Administration (USFDA) has made following inspections at the Hospira Healthcare
India in Sriperumbudur
conducted in last March-April.
The company said it had “voluntarily paused” production in the facility, which became a part of Pfizer
following its acquisition of US-based Hospira
in February 2015 in a $17-billion deal.
spokesperson said they were disappointed with the outcome of the drug regulator’s inspection. “We have submitted a comprehensive response to the USFDA
and are committed to implementing the necessary improvements and ensuring the quality of our medicines. Pfizer
is committed to product quality and we have voluntarily paused production at our Irungattukottai site.”
The facility had earlier received observations from the USFDA
as part of inspections in 2013 and 2015, according to reports.